USPTO Patent Applications - Biotech (C12N)

Epilepsy Treatment via Thalamus Bistable Opsin Gene Therapy

USPTO published patent application US20260091135A1 for Modulight Bio Ltd. covering methods of treating epilepsy using thalamus-administered bistable type II opsin gene therapy with light activation. The application (No. 19403102) was filed November 27, 2025, and published April 2, 2026. The invention targets drug-resistant epilepsy via optogenetic modulation of thalamic neural circuits.

ENHO gene therapy using Adropin for heart failure

The University of Pittsburgh filed a patent application (US20260091136A1) covering gene therapy methods using Adropin encoded by the ENHO gene for preventing and treating cardiometabolic diseases, specifically heart failure with preserved ejection fraction (HFpEF). The application was published on April 2, 2026.

Retron Gene Editing Patent for Human Cell Genome

USPTO published patent application US20260091137A1 for Retron directed gene editing technology applicable to human cell genome editing. The application, filed September 15, 2023, by inventors Brian Busser and colleagues, covers compounds, polypeptides, compositions, and nucleic acid molecules for genome editing. Key CPC classifications include gene editing enzymes and genetic constructs.

Variants of Coagulation Factor VIII and Uses Thereof

USPTO published patent application US20260091138A1 by Seattle Children's Hospital covering FVIII (coagulation factor VIII) protein variants with an N2118Q mutation for hemophilia A treatment. The application claims variants with reduced immunogenicity, higher gene expression, increased stability, and enhanced functional activity suitable for protein replacement therapy and gene therapy applications.

AAV Gene Therapy for Hypertrophic Cardiomyopathy

USPTO published patent application US20260091139A1 for AAV gene therapy compositions targeting reduced cardiac myosin binding protein C levels in subjects with hypertrophic cardiomyopathy. The application (filed September 22, 2023, Application No. 19113698) names six inventors including Peter Cameron Colosi and Eduard Ayuso. This is a publication notice with no immediate compliance obligations.

FOXG1 Gene Therapy Patent - Viral Vectors

USPTO published patent application US20260091140A1 for gene therapy constructs and viral vectors treating FOXG1 haploinsufficiency syndrome. Invented by Sarah Elizabeth Sinnett, the application (No. 19346144) includes FOXG1 encoding nucleic acids with miRNA regulatory elements to limit overexpression in vivo.

Broad Institute Gene Editing Patent for SMA Treatment

The USPTO published patent application US20260091141A1 by Broad Institute, Inc. covering gene editing methods, systems, and compositions for treating spinal muscular atrophy (SMA). The application (No. 19288071) was filed on August 1, 2025, and made publicly available on April 2, 2026. Inventors include David R. Liu, Mandana Arbab, and Zaneta Matuszek. The application covers modified messenger RNAs and delivery methods for treating microbial infections or improving subject health.

CureVac SE Bunyavirales vaccine patent application

CureVac SE Bunyavirales vaccine patent application

Nucleic Acid Vaccine Patent Application

USPTO published patent application US20260091104A1 filed by ModernaTX, Inc. for nucleic acid vaccine compositions and methods. The application (No. 19188713) covers ribonucleic acid vaccines encoding antigens, filed on April 24, 2025, and lists three inventors: Giuseppe Ciaramella, Axel Bouchon, and Eric Yi-Chun Huang.

RSV vaccine method, single dose, stronger immunity

The USPTO published patent application US20260091105A1 by inventors Peter L. Collins and Ursula J. Buchholz covering a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein. The vaccine reportedly induces a stronger immune response than previous candidates despite being more restricted in replication. The application (No. 18898953) was filed September 27, 2024.

Stabilized Enveloped Viruses by Spray-Drying and Lyophilization

The USPTO published patent application US20260091106A1 on April 2, 2026, disclosing compositions and methods for making thermostable enveloped viruses using spray-drying and lyophilization techniques. The inventions aim to reduce degradation, preserve virus activity and titer, and prolong storage stability for transport and later use. Application 19348562 was filed October 2, 2025 by inventors Coleman, Randolph, Schwartz, and Garcea.

Vaccine Comprising PBMCs Loaded with NKT Cell Ligand and Antigen

USPTO published patent application US20260091112A1 by CELLID CO., LTD. for an immunotherapeutic vaccine composition comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide (an NKT cell ligand) and tumor antigens. The filing date was September 15, 2023, with publication on April 2, 2026.

Biallelic Knockout of CTLA4

The USPTO published patent application US20260091113A1 by inventor Rafi Emmanuel covering compositions and methods for biallelic knockout of CTLA4 using RNA guide sequences. The application includes 4,891 sequence variants (SEQ ID NOs: 1-4891) with potential therapeutic applications. Filed September 18, 2023; published April 2, 2026.

ASXL1 Disruption in T Cells for Immunotherapy Enhancement

The USPTO published patent application US20260091115A1 filed by St. Jude Children's Research Hospital, Inc., covering modified immune effector cells with disrupted ASXL1 genes for enhanced immunotherapy function. The application includes claims for the modified T cells, methods of generating them, and methods for using them in adoptive cell therapy treatments for diseases.

Cell-Penetrating Peptides for Muscular Dystrophy Treatment

USPTO published patent application US20260091120A1 by Matthew Wood et al. covering cell-penetrating peptides with dual hydrophobic domains for treating genetic disorders, specifically Duchenne muscular dystrophy. The application (filed October 21, 2025) discloses peptide compositions and conjugates with therapeutic molecules. This is a publication of a pending application and does not yet grant enforceable patent rights.

Amino acid-modified lipids enable RNA delivery via lipid nanoparticles

USPTO published patent application US20260091126A1 for amino acid-modified lipids designed for RNA delivery via lipid nanoparticles (LNPs). The application, filed September 19, 2023, by inventors Kun Cheng and Pratikkumar Vinodchandra Patel, covers siRNA, mRNA, miRNA, shRNA, and oligonucleotide delivery formulations. The technology targets oncogene silencing applications.

Culture and Kit-of-Part of Bacterial Strains

USPTO published patent application US20260090557A1 for bacterial cheese culture strains and kits for manufacturing pasta-filata cheese. The application covers galactose-positive Streptococcus thermophilus strains and methods for producing stretched curd cheese using defined culture combinations. Filing date was December 10, 2025.

Lipid Nanoparticle mRNA Vaccines

USPTO published patent application US20260090989A1 by CureVac SE for lipid nanoparticle mRNA vaccine compositions. The application covers cationic lipids according to formulas (I)-(III), PEG lipids per formula (IV), and mRNA encoding antigens for influenza and rabies vaccination. The filing (Application No. 19409837) lists 14 inventors including Patrick Baumhof, Mariola Fotin-Mleczek, and Michael J. Hope.

Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods

The USPTO published patent application US20260090997A1 by Sorscher et al. disclosing lipid nanoparticle compositions comprising nucleic acids encoding therapeutic genes for treating cancer. The application was filed September 20, 2023, and published April 2, 2026. Inventors include researchers from Emory University and Georgia Institute of Technology working on targeted gene therapy delivery systems.

Pyocyanin Demethylases Engineered for Bacteria

The USPTO published patent application US20260091089A1 for engineered pyocyanin demethylases with amino acid replacements at positions A53, 173, A87, T91, M99, A129, and K141 of PodA. The application covers compositions, methods, and systems for interfering with bacterial viability through pyocyanin demethylase activity, including synergistic combinations with antibiotics. Application 19312182 was filed August 27, 2025.

Urate Oxidase-Albumin Conjugate Patent Application

USPTO published patent application US20260091090A1 for a urate oxidase-albumin conjugate invented by seven researchers. The conjugate uses three or more albumins conjugated through a linker to a urate oxidase variant, improving half-life and reducing immunogenicity. The invention addresses prevention and treatment of diseases caused by uric acid, such as gout and hyperuricemia.

Cardiac Xenograft Rejection Measurement Methods

The USPTO published patent application US20260091096A1 disclosing methods for measuring cardiac xenograft immune rejection progress. The application covers transgenic pig preparations with reduced glycan antigens (Sda/SDa-like and α-Gal) and recipient immunological response modifications targeting CD46, CD59, CD9, PROCR, and ANXA2. Inventors are Guerard W. Byrne and Christopher G.A. McGregor, with priority date September 15, 2025.

Cancer Treatment Patent - Two-Part Treatment Regime

The USPTO published patent application US20260091097A1 for a two-part cancer treatment regime involving antigen-specific T cell therapy followed by inflammation-inducing treatment. The application, filed on April 18, 2025, covers methods of treating cancer using sequential administration of treatments to generate tumor-specific immune responses. Inventors include Geoffrey Martin Lynn, Christopher Martin O'Brien Garliss, and others.

NADC34-like PRRSV-2 Vaccine Plasmid and Mutant Strain rBJ-VVL

Yangzhou University filed a patent application (US20260091100A1) with the USPTO for an rBJ-VVL plasmid and mutant NADC34-like PRRSV-2 strain with tropism for Marc-145 cells. The modified strain incorporates precise mutations at amino acid positions 91/97/98 of GP2a, enabling viral propagation and plaque formation in Marc-145 cells. This represents the first disclosed NADC34-like PRRSV-2-specific vaccine candidate derived from a Marc-145-adapted modified strain.

Patent Application for cDNA Synthesis and Transcriptome Profiling

The USPTO has published a patent application (US20260085309A1) for compositions and methods related to cDNA synthesis and transcriptome profiling. The application details optimized template switching oligonucleotides designed to improve reverse transcription specificity and prevent concatemer formation. This is a new patent application filing, not a final rule or guidance.

Patent Application for Antisense Oligonucleotide Targeting TDP-43 mRNA

The USPTO has published a patent application (US20260085310A1) filed by NIPPON SHINYAKU CO., LTD. The application describes an antisense oligonucleotide targeting TDP-43 mRNA or pre-mRNA for potential therapeutic use. The filing date was May 26, 2023.

Patent Application: Compositions and Methods for Reducing RNA Levels

The USPTO has published a new patent application (US20260085311A1) detailing compositions and methods for reducing RNA levels and treating diseases caused by toxic gain-of-function proteins. The application was filed on June 20, 2023.

Composition for Regulating Interfering Ribonucleic Acid Production

The USPTO has published a new patent application (US20260085312A1) detailing compositions and methods for regulating interfering ribonucleic acid (miRNA) production. The application describes techniques to decrease the bioavailability of target biomolecules by degrading or inactivating their corresponding messenger RNA (mRNA).

USPTO Patent Application for Modulating SMN2 RNA and Protein

The USPTO has published a patent application (US20260085313A1) detailing compounds, methods, and pharmaceutical compositions for modulating SMN2 RNA and protein. This application, filed on May 2, 2025, aims to ameliorate symptoms of neurodegenerative disorders.

Conjugated Oligonucleotide Compounds for Therapeutic Use

The USPTO has published a new patent application (US20260085314A1) for conjugated oligonucleotide compounds, methods of making them, and their therapeutic uses. The application was filed on May 16, 2025, by inventors Ahmad Ali Mortazavi, Viviana Mannella, and Muthusamy Jayaraman.

Engineered Polynucleotide for Cancer Treatment

The USPTO has published a patent application detailing an engineered polynucleotide designed to treat cancer by regulating gene expression. The application, filed on July 17, 2025, describes compositions and methods involving polynucleotides that interact with pre-mRNA and spliceosomes.

HMBOX1 Inhibitor for Muscle Atrophy Treatment

The USPTO has published a patent application (US20260085316A1) from Shanghai University detailing the use of a homeobox containing 1 (HMBOX1) inhibitor for the prevention and treatment of muscle atrophy. The application outlines findings from cellular and animal studies supporting the therapeutic potential of inhibiting HMBOX1 expression.

siRNA for AGT gene expression inhibition in hypertension treatment

The USPTO has published a new patent application (US20260085317A1) detailing modified oligonucleotide sequences designed as siRNAs to inhibit angiotensinogen (AGT) gene expression. The application suggests these siRNAs may be used in the development of treatments for hypertension and related diseases.

Patent Application: Cancer Treatment with Stat3 Decoy

The USPTO has published a new patent application (US20260085318A1) detailing methods for treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

Patent Application: Compositions for Treating CHD2 Haploinsufficiency

The USPTO has published a patent application (US20260085319A1) for compositions and methods to treat CHD2 haploinsufficiency. The application details a method of increasing Chromodomain Helicase DNA Binding Protein 2 (CHD2) in neuronal cells using a nucleic acid agent.

GalNAc Monomer for Liver-Targeted Nucleic Acid Drug Delivery

The USPTO has published a patent application detailing a GalNAc monomer for liver-targeted delivery of small nucleic acid drugs. The application, filed by inventors Zeao Huang et al., describes a compound that enhances drug efficacy through efficient liver targeting.

Patent Application: Iron Metabolism Targets for Obesity Treatment

The USPTO has published a new patent application (US20260085321A1) detailing methods for treating obesity by inhibiting specific iron metabolism genes. The application, filed on September 24, 2025, by inventor Richard Possemato, proposes inducing weight loss through increased lipid catabolism.

Patent Application for Metabolism Disease Therapeutic Agents

The USPTO has published a new patent application (US20260085322A1) for therapeutic agents targeting metabolism-associated diseases, such as MAFLD. The application was filed on September 6, 2023, by inventors from the USPTO.

Patent Application for Plant Regulatory Elements and Uses

The USPTO has published a patent application (US20260085324A1) detailing novel synthetic small nuclear RNA (snRNA) promoters for CRISPR-mediated gene modifications in plants. The application, filed on October 3, 2025, includes methods and compositions for developing plants with modified genomes using these promoters.

Patent Application: Disruption of GROOT Gene Function Increases Plant Biomass

The USPTO has published a patent application (US20260085325A1) from the Salk Institute for Biological Studies detailing methods to enhance plant biomass and seed size by reducing the expression of GROOT1, GROOT2, and GROOT3 genes. The application describes compositions and transformed plants generated using these methods.

Viral Protein Expression Patent Application

The USPTO has published a new patent application, US20260085328A1, filed on September 8, 2023. The application describes methods and systems for producing adeno-associated virus (AAV) particles using insect cells.

US Patent Application for PDCD1 Knockout RNA Molecule

The USPTO has published a new patent application (US20260085331A1) for an RNA molecule designed for biallelic knockout of PDCD1. The application, filed on September 18, 2023, details compositions comprising RNA molecules with specific guide sequences and their methods of use.

Chimeric Transposases and Fusion Proteins Patent Application

The USPTO has published a new patent application (US20260085332A1) detailing chimeric transposases and fusion proteins. The application, filed on October 3, 2025, by inventors Joseph S. Lucas, Blair B. Madison, and Olga Batalov, covers polynucleotides, vectors, and methods for modifying cells using these proteins.

Engineered Ketoreductases for Chiral Alcohol Preparation

The USPTO has published a patent application (US20260085334A1) for engineered ketoreductase polypeptides developed by Enzymaster (Ningbo) Bio-Engineering Co., Ltd. The patent describes enzymes capable of preparing chiral alcohols with high catalytic activity, stereoselectivity, thermal stability, and solvent tolerance.

Method for Producing Oil Composition via Biomass Fermentation

The USPTO has published a patent application detailing a method for producing an oil composition through the fermentation of biomass using specific yeast strains. The application outlines a preparation stage, a fermentation stage with controlled temperature and pH, and an oil procurement stage involving mechanical cell lysis.

Patent Application for Pseudomonas Recombinant Protein Expression

The USPTO has published a new patent application, US20260085338A1, detailing a Pseudomonas sp. strain for recombinant protein expression. The application was filed on September 6, 2023, and relates to novel expression systems for biotechnological applications.

Method for Detecting Polynucleotide Analyte Using CRISPR/Cas Effector

The USPTO has published a new patent application detailing a method for detecting polynucleotide analytes using CRISPR/Cas effector technology. The application, filed by inventors from USPTO, describes a method involving a cleaving agent with flap endonuclease activity and a type V CRISPR/Cas effector protein, specifically a Cast2 protein.

Methods for rapid multiplex HLA genotyping and transcript quantitation

The USPTO has published a new patent application detailing methods for rapid multiplex HLA genotyping and transcript quantitation using nanopore technology. The application, assigned to The University of North Carolina at Chapel Hill, outlines techniques for determining HLA status and genotyping donor cells for transplantation.

Breast Cancer Detection Kit, Device, and Method Patent Application

The USPTO has published a patent application (US20260085359A1) from TORAY INDUSTRIES, INC. for a breast cancer detection kit, device, and method. The application describes a kit or device comprising nucleic acids that specifically bind to a miRNA in a subject's sample, and a method for detecting breast cancer by measuring the miRNA in vitro.

Alpha-amylase variants and polynucleotides patent application

The USPTO has published a new patent application, US20260085261A1, from Novozymes A/S concerning alpha-amylase variants and related polynucleotides. The application details specific molecular constructs and their potential uses.